US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Genvec

7.19

0.0000

Volume:- -

Turnover:- -

Market Cap:16.36M

PE:-2.25

High:7.19

Open:7.19

Low:7.19

Close:7.19

52wk High:10.44

52wk Low:2.70

Shares:2.27M

Float Shares:1.57M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2000

ROE:--

ROA:--

PB:28.06

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Genvec

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.genvec.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the United States. It designs, tests, and manufactures adenoviral-based product candidates. The companys lead product candidate, CGF166 is in Phase I/II clinical trials for the treatment of hearing loss and balance disorders. It is also developing GV2311 vaccine for respiratory syncytial virus; and GV2207 vaccine for the treatment of herpes simplex virus. The company has a collaboration agreement with Novartis AG to develop CGF166. It also has collaboration agreement with TheraBiologics, Inc. to develop cancer therapeutics; National Institute of Allergy and Infectious Diseases to create and test various malaria vaccine candidates; and Merial Limited to develop and commercialize vaccine and anti-viral candidates for the prevention and containment of foot-and-mouth diseases in livestock and other animals. The company was founded in 1992 and is based in Gaithersburg, Maryland.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GNVC/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GNVC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNVC\",,,,,undefined,":{"symbol":"GNVC","market":"US","secType":"STK","nameCN":"Genvec","latestPrice":7.193,"timestamp":1505246400000,"preClose":7.193,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":1565191,"shares":2274000,"eps":-3.2,"marketStatus":"Closed","change":0,"latestTime":"09-12 16:00:00 EDT","open":7.193,"high":7.193,"low":7.193,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.2,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770973200000},"marketStatusCode":5,"adr":0,"listingDate":976597200000,"exchange":"NASDAQ","adjPreClose":7.193,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNVC\",,,,,undefined,":{"symbol":"GNVC","floatShares":1565191,"roa":"--","roe":"--","lyrEps":0,"shares":2274000,"dividePrice":0,"high":7.193,"amplitude":0,"preClose":7.193,"low":7.193,"week52Low":2.7,"pbRate":"28.06","week52High":10.44,"institutionHeld":0.3028,"latestPrice":7.193,"eps":-3.2,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.2,"open":7.193,"prevYearClose":7.193},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GNVC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-05-10","symbol":"GNVC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1494388800000,"reportTimeType":"","actualEps":-1.88},{"market":"US","date":"2016-11-04","symbol":"GNVC","fiscalQuarterEnding":null,"expectedEps":-0.08,"name":null,"time":"","type":"earning","dateTimestamp":1478232000000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-08-05","symbol":"GNVC","fiscalQuarterEnding":null,"expectedEps":-0.1,"name":null,"time":"","type":"earning","dateTimestamp":1470369600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-05-12","symbol":"GNVC","fiscalQuarterEnding":null,"expectedEps":-0.09,"name":null,"time":"","type":"earning","dateTimestamp":1463025600000,"reportTimeType":"","actualEps":-0.11},{"market":"US","date":"2016-03-09","symbol":"GNVC","fiscalQuarterEnding":null,"expectedEps":-0.08,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1457499600000,"reportTimeType":"pre","actualEps":-0.1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GNVC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GNVC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.genvec.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":-0.0046},{"period":"3month","weight":0.0296},{"period":"6month","weight":0.0754},{"period":"1year","weight":0.1431},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the United States. It designs, tests, and manufactures adenoviral-based product candidates. The companys lead product candidate, CGF166 is in Phase I/II clinical trials for the treatment of hearing loss and balance disorders. It is also developing GV2311 vaccine for respiratory syncytial virus; and GV2207 vaccine for the treatment of herpes simplex virus. The company has a collaboration agreement with Novartis AG to develop CGF166. It also has collaboration agreement with TheraBiologics, Inc. to develop cancer therapeutics; National Institute of Allergy and Infectious Diseases to create and test various malaria vaccine candidates; and Merial Limited to develop and commercialize vaccine and anti-viral candidates for the prevention and containment of foot-and-mouth diseases in livestock and other animals. The company was founded in 1992 and is based in Gaithersburg, Maryland.","exchange":"NASDAQ","name":"Genvec","nameEN":"Genvec"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"GNVC\",market:\"US\",,,undefined,":null}}